Trial Profile
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir; Emtricitabine/tenofovir disoproxil fumarate
- Indications Hepatitis B; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Alliance
- Sponsors Gilead Sciences
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.
- 06 Mar 2024 According to Gilead Sciences Media Release, data from the study were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
- 06 Mar 2024 Results of subgroup analysis presented in the Gilead Sciences Media Release.